Drug Type Small molecule drug |
Synonyms JS230 |
Target |
Action antagonists, inhibitors, stimulants |
Mechanism EGFR antagonists(Epidermal growth factor receptor erbB1 antagonists), PARP inhibitors(Poly (ADP-Ribose) polymerase inhibitors), DNA damage stimulants |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Molecular FormulaC45H45BrFN11O6S |
InChIKeyHDBSHKDWWYJNGT-UHFFFAOYSA-N |
CAS Registry2457232-23-2 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Prostatic Cancer | Preclinical | Canada | 11 Jun 2020 |